Last reviewed · How we verify

Priligy (DAPOXETINE)

Phase 3 active Small molecule Under review Quality 10/100

Priligy (generic name: DAPOXETINE) is a dapoxetine drug. It is currently in Phase 3 development for Premature ejaculation.

Dapoxetine works by blocking the reuptake of serotonin in the brain, allowing it to stay in the synaptic cleft for longer and increasing the time it takes to ejaculate.

Priligy, also known as dapoxetine, is a small molecule that inhibits the sodium-dependent serotonin transporter, a mechanism that affects serotonin levels in the body. It is primarily used to treat premature ejaculation, a condition where a man ejaculates earlier than he or his partner would like during sexual activity.

Likelihood of approval
58.3% vs 58.3% industry baseline
If approved by FDA: likely 2028–2030
Steps remaining: NDA/BLA submission
Confidence: High
Why this estimate
  • Baseline phase 3 → approval rate +58.3pp
    Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
Predicted approval windows by jurisdiction (conditional on FDA approval)
Regulator Country Likely year Lag vs FDA
FDA US 2028–2030
EMA EU 2029–2031 +0.7 yr
MHRA GB 2029–2031 +0.7 yr
Health Canada CA 2029–2032 +0.9 yr
TGA AU 2029–2032 +1.2 yr
PMDA JP 2029–2032 +1.5 yr
NMPA CN 2030–2033 +2.3 yr
MFDS KR 2029–2032 +1.4 yr
CDSCO IN 2029–2033 +1.8 yr
ANVISA BR 2030–2033 +2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic nameDAPOXETINE
Drug classdapoxetine
TargetSodium-dependent serotonin transporter
ModalitySmall molecule
Therapeutic areaOther
PhasePhase 3

Mechanism of action

Imagine serotonin as a messenger that helps you feel pleasure and relaxation. When you ejaculate, serotonin is quickly taken back into the brain, making it harder to control your body's response. Dapoxetine helps keep serotonin in the brain for longer, giving you more time to enjoy sex before ejaculation.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Priligy

What is Priligy?

Priligy (DAPOXETINE) is a dapoxetine drug, indicated for Premature ejaculation.

How does Priligy work?

Dapoxetine works by blocking the reuptake of serotonin in the brain, allowing it to stay in the synaptic cleft for longer and increasing the time it takes to ejaculate.

What is Priligy used for?

Priligy is indicated for Premature ejaculation.

What is the generic name of Priligy?

DAPOXETINE is the generic (nonproprietary) name of Priligy.

What drug class is Priligy in?

Priligy belongs to the dapoxetine class. See all dapoxetine drugs at /class/dapoxetine.

What development phase is Priligy in?

Priligy is in Phase 3.

What are the side effects of Priligy?

Common side effects of Priligy include Nausea, Dizziness, Headache, Somnolence, Palpitations, Dry Mouth.

What does Priligy target?

Priligy targets Sodium-dependent serotonin transporter and is a dapoxetine.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing